Developing a new medication to help prevent relapse in methamphetamine users
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse
This study is testing a new medication called MT-110 to help people with methamphetamine use disorder stay off the drug and avoid relapse, since there aren't any approved treatments available right now.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project ID | NIH-10682482 on NIH RePORTER |
What this research studies
This research focuses on creating a novel medication, MT-110, aimed at preventing relapse in individuals with methamphetamine use disorder. Currently, there are no FDA-approved medications for this condition, and existing behavioral therapies often fall short, leading to high relapse rates. The study investigates how MT-110, a nonmuscle myosin II inhibitor, can disrupt the motivation to seek methamphetamine, thereby supporting individuals in maintaining abstinence. The research is in the early stages, with plans to begin clinical trials soon.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with methamphetamine use disorder who are seeking treatment options.
Not a fit: Patients who are not struggling with methamphetamine use disorder or those who have not previously used methamphetamine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed pharmacotherapy option for individuals struggling with methamphetamine use disorder, potentially reducing relapse rates significantly.
How similar studies have performed: While there have been various approaches to treating substance use disorders, the specific use of nonmuscle myosin II inhibitors is novel and has not been extensively tested in this context.
Where this research is happening
Jupiter, United States
- Myosin Therapeutics INC. — Jupiter, United States (Active)
Researchers
- Principal investigator: Young, Erica J — Myosin Therapeutics INC.
- Study coordinator: Young, Erica J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.